Myocardial Hypertrophy Overrides the Angiogenic Response to Hypoxia by Choi, Yeong-Hoon et al.
Myocardial Hypertrophy Overrides the Angiogenic
Response to Hypoxia
Yeong-Hoon Choi
1¤*, Douglas B. Cowan
2, Meena Nathan
1, Dimitrios Poutias
2, Christof Stamm
1, Pedro J.
del Nido
1, Francis X. McGowan, Jr.
2
1Department of Cardiac Surgery, Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America, 2Department of
Anesthesiology, Perioperative and Pain Medicine, Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Background: Cyanosis and myocardial hypertrophy frequently occur in combination. Hypoxia or cyanosis can be potent
inducers of angiogenesis, regulating the expression of hypoxia-inducible factors (HIF), vascular endothelial growth factors
(VEGF), and VEGF receptors (VEGFR-1 and 2); in contrast, pressure overload hypertrophy is often associated with impaired pro-
angiogenic signaling and decreased myocardial capillary density. We hypothesized that the physiological pro-angiogenic
response to cyanosis in the hypertrophied myocardium is blunted through differential HIF and VEGF-associated signaling.
Methods and Results: Newborn rabbits underwent aortic banding and, together with sham-operated littermates, were
transferred into a hypoxic chamber (FiO2=0.12) at 3 weeks of age. Control banded or sham-operated rabbits were housed in
normoxia. Systemic cyanosis was confirmed (hematocrit, arterial oxygen saturation, and serum erythropoietin). Myocardial
tissue was assayed for low oxygen concentrations using a pimonidazole adduct. At 4 weeks of age, HIF-1a and HIF-2a protein
levels, HIF-1a DNA-binding activity, and expression of VEGFR-1, VEGFR-2, and VEGF were determined in hypoxic and normoxic
rabbits. At 6 weeks of age, left-ventricular capillary density was assessed by immunohistochemistry. Under normoxia, capillary
density was decreased in the banded rabbits compared to non-banded littermates. As expected, non-hypertrophied hearts
responded to hypoxia with increased capillary density; however, banded hypoxic rabbits demonstrated no increase in
angiogenesis. This blunted pro-angiogenic response to hypoxia in the hypertrophied myocardium was associated with lower
HIF-2a and VEGFR-2 levels and increased HIF-1a activity and VEGFR-1 expression. In contrast, non-hypertrophied hearts
responded to hypoxia with increased HIF-2a and VEGFR-2 expression with lower VEGFR-1 expression.
Conclusion: The participation of HIF-2a and VEGFR-2 appear to be required for hypoxia-stimulated myocardial
angiogenesis. In infant rabbit hearts with pressure overload hypertrophy, this pro-angiogenic response to hypoxia is
effectively uncoupled, apparently in part due to altered HIF-mediated signaling and VEGFR subtype expression.
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Introduction
Left-ventricular (LV) pressure-overload hypertrophy is a signif-
icant risk factor in adult and pediatric patients undergoing cardiac
surgery. Hearts from these patients exhibit progressive contractile
dysfunction, dilation of the ventricular wall, and increased
vulnerability to ischemia-reperfusion injury as a consequence of
numerous factors that include impaired glucose uptake and a
reduction in high-energy phosphate concentrations [1,2]. We have
previouslyestablishedthatcapillarydensityissignificantlydecreased
in chronically hypertrophied hearts, resulting in greater diffusion
distances that could act to limit the supply of energy and oxygen to
this metabolically-demanding organ [3].
In children with congenital heart disease, myocardial hypertro-
phy is commonly associated with hypoxia and cyanosis. Under
normal circumstances, tissue hypoxia induces angiogenesis
through increased expression and activity of hypoxia-inducible
transcription factors (HIFs) [4]. HIFs are basic helix-loop-helix
(bHLH) transcription factors that increase expression of genes
involved in regulating oxygen delivery capacity (e.g. erythropoietin
and ceruloplasmin), glucose transport and metabolism (e.g. the
glucose transporters GLUT 1–3, and hexokinase), and angiogen-
esis (e.g. VEGF and VEGFRs). Though it may assumed that the
pro-angiogenic effects of tissue hypoxia would help counteract the
relative capillary deficiency in the hypertrophied heart, clinical
experience demonstrates that myocardial dysfunction and suscep-
tibility to ischemia-reperfusion injury is higher in patients with
combined hypertrophy and cyanosis. Therefore, we reasoned that
activation of angiogenesis-related signalling pathways would be
suppressed in response to hypertrophy, with resultant loss of pro-
angiogenic capacity. Accordingly, we first tested the hypothesis
that an increase in capillary density during hypoxia is blunted in
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4042hearts subjected to pressure-overload hypertrophy and then
determined the HIF and VEGFR-subtype expression profile to
identify possible points of interference.
Materials and Methods
Animal care
Animals received humane care in compliance with the Principles
of Laboratory Animal Care formulated by the National Society of Medical
Research and the Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Sciences and published by the
National Institutes of Health (NIH Publication No. 86-23, revised
1996). The Institutional Animal Care and Use Committee
approved all experiments.
Experimental Groups
Ten day old New Zealand White rabbits underwent aortic
banding surgery (BAND) or sham operation (SHAM) as previously
described [5,6]. Briefly, pressure-overload hypertrophy of the left
ventricle was achieved by placing 2-0 silk suture around the
descending thoracic aorta, distal to the ligamentum arteriosum.
Implantation of a fixed constriction in a rapidly growing animal
induced pressure-overload ventricular hypertrophy beginning after
2–3 weeks of age. The control animals underwent the sham-
procedure, including general anesthesia, lateral thoracotomy, and
blunt dissection of the descending aorta. At 3 weeks of age,
following recovery and weaning from mothers, the rabbit pups
were transferred into a hypoxia chamber (HYPOX; Coy
Laboratory Products, Grass Lake, MI, USA) or were housed in
normal oxygen conditions (NORM). Each experimental group
contained 7 animals. The oxygen level inside the chamber was
reduced to a FiO2 of 0.12 by nitrogen replacement [7–9].
Humidity, air pressure, temperature, and CO2 levels were
maintained at ambient levels. Food and water were provided ad
libitum. A systemic cyanotic response was confirmed by determin-
ing hemoglobin and hematocrit levels through daily blood gas
analyses using a Stat Profile 9 blood gas analyzer (Nova
Biochemical, Waltham, MA).
In preliminary experiments (data not shown), protein expression
and activity assays showed significant differences after 1 week of
hypoxia (4 weeks post-partum), but significant changes in capillary
density were not observed until week 3 (6 weeks post-partum).
Subsequently, protein assays were performed at 4 weeks post-
partum and capillary density was determined at 6 weeks post-
partum (n=7 at each time). At 4 or 6 weeks of age, respectively,
the animals were anesthetized by intravenous injection of
Ketamine/Xylazine/heparin (100 mg/kg/10 mg/kg/200 IU/
kg). Hearts were rapidly excised, mounted to a modified
Langendorff apparatus and perfused for 5 minutes at constant
pressure (80 mm Hg) using modified Krebs-Henseleit buffer
[10,11]. Hearts were collected and processed for immunohisto-
chemistry or used for protein isolation. All animals in the HYPOX
groups were euthanized under hypoxic conditions. A separate set
of animals was injected intraperitoneally 30 minutes prior to
euthanasia with 100 mg/kg HypoxyProbe
TM-1 reagent (Millipore,
Billerica, MA).
Immunoblot Analyses and ELISA
Tissue samples from the lateral free wall of the left ventricle
were obtained and processed for both total and nuclear protein as
previously described [12,13]. HIF-1 and -2, VEGF, and VEGFR-
1 and -2 protein levels were determined using total tissue lysates,
whereas HIF-1 DNA-binding activity was determined using
nuclear extracts. SDS-PAGE and transfer to nitrocellulose were
performed using standard procedures and equal protein loading of
the wells was confirmed by Coomassie Brilliant Blue R250 staining
of the gels. Following incubation in 5% non-fat milk suspended in
Tris-buffered saline containing 0.1% Tween 20 (TBS-T), the
nitrocellulose membranes were incubated with primary antibodies
at 4uC overnight. For specific protein detection, the following
primary monoclonal antibodies were used: anti-HIF-1a (1:500,
Figure 1. Cumulative data of the LV-to-bodyweight ratio of all experimental groups at 4 weeks of age (*p,0.01). The animals that
underwent aortic banding developed significant LV hypertrophy starting at one week after surgery. Although hypoxia affected the overall growth of
the animal, the development of LV hypertrophy was not significantly altered.
doi:10.1371/journal.pone.0004042.g001
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Biologicals, Littleton, CO), anti-VEGFR-1 (1:100, Millipore,
Billerica, MA) and anti-VEGFR-2 (1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA). To determine VEGF expression levels
we applied an anti-VEGF antibody, which recognizes the 121,
165, 189, and 206 isoforms (1:2000, Millipore, Billerica, MA).
Primary antibodies were detected with horseradish peroxidase-
conjugated goat anti-mouse secondary antibodies (Amersham
Biosciences, Piscataway, NJ) in TBS-T at the manufacturers
suggested dilutions and visualized using an Amersham ECL
TM kit
(GE Healthcare, Piscataway, NJ). To determine erythropoietin
(EPO) serum levels, blood samples were obtained from all animals
immediately before euthanasia according to the manufacturer’s
recommendation. Following centrifugation, normalized serum
fraction samples were analyzed using the Human Erythropoietin
QuantikineH IVD ELISA Kit (R&D Systems, Minneapolis, MN).
Electrophoretic Mobility Shift Assay
The DNA-binding activity of HIF-1 was determined by
electrophoretic mobility shift assay[14]. Briefly, each 20 ml
Figure 2. Cumulative data of blood gas analyses of sham-operated animals that have been exposed to chronic hypoxia. The shown
data demonstrate immediate changes of arterial oxygen saturation upon exposure to hypoxia (FiO2=0.12) (2a) followed by increased hematocrit
(2b). The banded animals responded to hypoxia in the same manner when compared to non-banded animals (not shown) (*p,0.01).
doi:10.1371/journal.pone.0004042.g002
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5 mM MgCl2, 1 mM dithiothreitol, 1 mM EDTA (pH 8.0), 25%
glycerol, 0.2% Triton X-100, 16Complete
TM protease inhibitor,
2.0 mg poly(dI-dC)?poly(dI-dC) (Amersham Biosciences), and
0.25 ng of double stranded, end-labeled HIF-1 consensus
oligonucleotides (Santa Cruz Biotechnology) [15]. Some reactions
contained unlabeled oligonucleotides (either identical, with
mutated binding sites, or unrelated DNA of the same size). As a
positive control, nuclear extracts were prepared from COS-7 cells
treated with 0.15 mM cobalt chloride (CoCl2) for 16 hours.
Probes were labeled with [c-
32P] ATP and polynucleotide kinase
using standard techniques. Labeled DNA was purified with
ProbeQuant G-50 columns (Amersham Biosciences). Densitome-
try of immunoblots and EMSA autoradiograms was accomplished
using the NIH software Scion Image.
Immunohistochemistry
To quantify myocardial capillary density, isolated hearts were
perfused for 15 minutes with Krebs-Henseleit buffer containing
5 mM FITC-conjugated Lycopersicon esculentum lectin (Sigma-
Aldrich, St. Louis, MO) [16]. The hearts were perfused for
another 5 minutes with buffer alone and then fixed under pressure
for 10 minutes with 4% paraformaldehyde (pH 7.4) (PFA). After
passive fixation for 3 days in fresh PFA, heart tissue was paraffin-
embedded and sectioned. Histological slides were deparaffinized,
rehydrated in descending concentrations of ethanol, and incubated
with 49,6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad,
CA,) for nuclear counterstaining. The slides were mounted with
cover-slips using fluorescent mounting medium (Dako USA,
Carpinteria, CA) and visualized on a Zeiss Axiovert 200 M
microscope (Carl Zeiss, Thornwood, NY). Images were acquired
with a Princeton Instruments MicroMAX 1300Y/S CCD camera
(Roper Industries, Duluth, GA) and analyzed using MetaMorph
6.2. software (Molecular Devices, Downingtown, PA). To
determine capillary density, 15 randomly selected fields of tissue
cross-sections from 3 slides per animal were examined (taken from
the apex, the middle and the heart base). To detect hypoxia
(pO2,10 mmHg at tissue level), hearts were examined for
pimonidazole adduct formation [17]. After sectioning, adducts
were detected by immunohistochemistry, using a monoclonal
antibody (1:50) that was detected with an Alexa FluorH488-
conjugated secondary goat anti-mouse antibody (Invitrogen,
Carlsbad, CA).
Statistical analyses
Numeric data are expressed as mean6SD and statistical
analyses were performed using release 15.0 of the SPSS software
package (SPSS, Chicago, IL). Capillary density data were tested
for significance by one-way ANOVA applying Bonferroni’s
correction for multiple comparisons. If normal distribution and
equal variance testing was passed, Student’s t-test was applied to
compare individual data sets. A two-tailed probability value of less
than 0.05 was considered statistically significant.
Figure 3. Indirect visualization of hypoxia in the myocardium. Animals from all four experimental groups were injected with 100 mg/kg
pimonidazole intraperitoneally 30 minutes before euthanasia. The microscopic images show the detection of pimonidazole adducts, which form only
under hypoxic conditions (pO2,10 mm Hg at tissue level). The top panel (A–D) shows antibody-based detection of pimonidazole adducts (green
fluorescence); the bottom panel (E–H) demonstrates staining of nuclear DNA with DAPI (blue; the scale bar represents 25 mm). Animals that were
exposed to chronic hypoxia showed positive staining for pimonidazole adducts, while animals that have been housed under normoxic conditions
were tested negative for pimonidazole adducts. All images were acquired with identical acquisition settings (exposure time, light intensity, and
neutral density filters). Surprisingly, although no hypoxia was observed in animals of the BAND NORM group, those animals showed increased
expression of HIF-1a.
doi:10.1371/journal.pone.0004042.g003
Table 1. Summary of serum erythropoietin concentrations in
mIU/mL.
SHAM BAND p
NORM 9.8263.63 7.9162.98 0.894
HYPOX 31.7766.93 28.8167.03 0.739
p ,0.001 ,0.001
Hypoxia increased EPO concentrations equally and significantly in both the
sham and banded animals. Data are Mean6S.D., N=6–8 animals/group.
doi:10.1371/journal.pone.0004042.t001
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Induction of ventricular hypertrophy
In preliminary experiments, hearts from each experimental
group were harvested on a weekly basis, and the LV wet weight-to-
body weight ratio was determined. Progression of ventricular
hypertrophy was also confirmed by echocardiographic observa-
tions as previously reported [5]. Animals with aortic banding
developed progressive LV hypertrophy with a peak of ‘compen-
sated’ hypertrophy at approximately 4 weeks of age. Left
ventricular dilation and failure, leading to decompensation and
death, ensued at approximately 8 weeks post-partum. Our results
showed no difference in the development of LV-hypertrophy
between animals that were exposed to hypoxia and those subjected
to normoxic conditions. Figure 1 shows the LV wet weight-to-
body weight ratio at 4 weeks of age; confirming the development
of significant LV hypertrophy in rabbits following aortic banding.
Hypoxia and systemic cyanosis
The FiO2 of 0.12 induced significant cyanosis and a typical
physiological response in rabbits [9]. Daily arterial blood samples
confirmed an immediate drop of the arterial oxygen saturation
(SaO2) upon exposure to hypoxia compared with animals housed
under normoxic conditions (Figure 2a). In animals that underwent
aortic banding, the systemic response to hypoxia was not
statistically different compared to non-banded animals (SHAM).
Figure 3 shows representative immunohistochemical staining for
pimonidazole adducts after exposure to hypoxia. The animals in
the HYPOX groups showed positive staining with no differences
between the sham operation and aortic banding groups (SHAM
HYPOX and BAND HYPOX). The staining was consistent
within the entire cross-section of the heart and showed no
significant regional differences. Contrary to the hypothesis that
pressure-overload hypertrophy would result in myocardial hypox-
ia, no positive pimonidazole adduct staining was detectable in
animals of the BAND NORM group.
Erythropoietin (EPO) serum levels were determined by ELISA
at four weeks of age. As a marker for the systemic response to
reduced arterial partial oxygen pressure, animals that were
exposed to chronic hypoxia showed a significant increased of
EPO in the serum compared to animals under normoxia, with a
consequent increase of hematocrit (Table One and Figure 2b,
Figure 4. Capillary density. A) Representative micrographs of left ventricular cross-sections (6 mm thickness) showing capillary vessels in all
groups (as visualized by FITC-labeled lectin, scale bar represents 100 mm). B) Vessel density quantification assessed by computer-based image analysis
is shown in 4b (*p,0.01, shown as mean6SE). As a physiologic response to chronic hypoxia, sham operated animals showed a significant increase in
capillary density. Animals with left ventricular hypertrophy showed a relative decrease in capillary density under normoxia. Chronic hypoxia failed to
induce an increase of capillary density in hypertrophying LV myocardium.
doi:10.1371/journal.pone.0004042.g004
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between the respective banded or sham operated groups (Table 1).
Capillary density
Histological evaluation of myocardial vascular architecture
displayed dense capillary distribution in the left ventricle, which
was significantly increased by hypoxia in sham-operated animals.
As previously observed, the capillary density was significantly
reduced in animals with pressure-overload hypertrophy [16];
however, hypoxia (normally a significant activator of angiogenesis)
did not induce increased vascularization in hypertrophied hearts.
There was no difference in capillary density between normoxic
banded animals and hypoxic banded animals (NORM BAND vs.
HYPOX BAND; 1251.26213.6 vs. 1304.36253.4, p=0.64),
indicating a blunted angiogenic response to hypoxia. Represen-
tative photomicrographs and quantitative capillary density data,
shown in Figure 4, demonstrated the pro-angiogenic effect of
hypoxia in hearts of non-banded rabbits, which was negated by
myocardial hypertrophy.
HIF-1/2, VEGF, and VEGFR-1/2 expression
HIF-1/2 are the key regulators of the hypoxic response[18]. To
determine expression of those proteins, as well as their target genes
VEGF and VEGFR-1/2, immunoblotting was performed
(Figure 5) and densitometry data are summarized in Table 2.
Under normoxic conditions, there was nearly complete suppres-
sion of HIF-1a expression in the hearts of sham-operated animals
(SHAM NORM), but HIF-1a significantly increased in response
to hypoxia (SHAM HYPOX). In contrast, animals with aortic
banding (BAND NORM) showed elevated expression of HIF-1a
under normoxia, and the elevated HIF-1a expression was not
further altered by hypoxia (BAND HYPOX). HIF-2a was not
detectable in sham-operated or aortic banded animals under
normoxia. Under hypoxic conditions, only the animals of the
SHAM HYPOX group responded with increased HIF-2a
expression, whereas aortic banded animals (BAND HYPOX)
showed no change in HIF-2a expression.
In sham-operated normoxic hearts, very little VEGF receptor-1
protein was detected, and there was apparently no increase in
VEGFR-1 protein in response to LV hypertrophy alone. VEGFR-
1 expression, which can be regulated by HIF-1a and/or HIF-2a,
was slightly increased under hypoxia (SHAM HYPOX). In hearts
subjected to both hypoxia and hypertrophy (BAND HYPOX),
increased expression of VEGFR-1 was much more pronounced.
Similarly, the baseline expression of VEGFR-2 was not different in
animals that underwent sham operation or aortic banding surgery
under normoxia. On the other hand, a significant increase of
VEGFR-2 expression under hypoxia was detected in animals of
the sham-operated group. In animals with a banded thoracic aorta
(BAND HYPOX), the VEGFR-2 response to hypoxia was
significantly suppressed. In contrast, VEGF protein was expressed
constitutively and showed no significant change in the different
groups under either normoxia or hypoxia.
HIF-1a DNA-binding activity
To determine the activity of HIF-1a, nuclear protein was
analyzed by the electrophoretic mobility shift assay [15]. HIF-1a
DNA-binding activity paralleled the protein expression data
described above. There was very little specific binding to labeled
HIF-1a consensus sequences in sham-operated animals under
normoxia. Upon exposure to hypoxia, nuclear HIF-1a DNA-
binding was significantly increased. In aortic banded animals,
binding to the HIF-1 consensus sequence was elevated under
normoxic conditions, and further increased as a result of exposure
to hypoxia (Figure 6).
Discussion
Our principal finding is that the normal pro-angiogenic
response to hypoxia seen in non-hypertrophied hearts fails to
occur in left ventricular myocardial hypertrophy. While capillary
density increases in response to hypoxia in non-hypertrophied
hearts, it remains unchanged in hearts that have a pressure-
overload hypertrophic response superimposed on hypoxia. This
likely renders the hypertrophied heart more susceptible to
ischemia-reperfusion injury and potentially contributes to cardio-
myocyte dysfunction and ventricular failure. At the molecular
level, it appears that hypoxia-induced HIF-2a and VEGFR-2
expression are reduced in left ventricular hypertrophy, and that
these are necessary, with or without the participation of HIF-1a,t o
promote angiogenesis in response to hypoxia. Conversely,
hypoxia-mediated induction and activation of HIF-1a and
Figure 5. Representative immunoblots with specific detection
of HIF-1a, HIF-2a in nuclear protein extracts and VEGFR-1,
VEGFR-2, and VEGF in total protein extracts obtained at four
weeks of age. In response to hypoxia sham operated animals showed
apparent activation of HIF-1a and HIF-2a based upon increased nuclear
protein concentrations, along with increased expression of VEGFR-1 and
VEGFR-2. Pressure load appeared to increase HIF-1a activation and
perhaps modestly increase VEGRF-1 expression, without changing HIF-
2a activation. LV hypertrophy prevented hypoxia-induced increases in
HIF-2a activation, decreased VEGFR-2 expression, and increased VEGFR-
1 expression. VEGF levels were not affected by hypoxia or aortic
banding.
doi:10.1371/journal.pone.0004042.g005
Table 2. Summary of densitometry analyses of normalized
protein levels of HIF-1a, VEGFR-1, HIF-2a, VEGFR-2, and VEGF
obtained by immunoblotting using lysates isolated from
aortic banded and sham operated animals exposed to either
normoxia or hypoxia.
SHAM
NORM
BAND
NORM
SHAM
HYPOX
BAND
HYPOX
HIF-1a + +++ +++ +++
VEGFR-1 +/2 +/2 ++ +
VEGFR-2 + + +++ +
HIF-2a 22++ +/2
VEGF +++ +++ +++ +++
Results are based upon 3–5 hearts/group.
doi:10.1371/journal.pone.0004042.t002
Angiogenesis Inhibition
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e4042Figure 6. A) Representative autoradiograph of electrophoretic shift assay (EMSA) of specific binding of HIF-1a nuclear protein. Increased activity of
HIF-1a was detected in hypertrophic myocardium under normoxic conditions with further elevation under hypoxia. As a positive HIF-1a control,
nuclear extracts were obtained from COS-7 (COS) cells treated with 0.15 mM CoCl2 for 16 hours and subjected to parallel EMSAs. B) Densitometry
analysis of HIF-1a EMSAs.
doi:10.1371/journal.pone.0004042.g006
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increased expression of VEGFR-1 in hearts that are both hypoxic
and hypertrophied. Taken together, the hypoxia-induced angio-
genic response in is uncoupled in hypertrophied hearts, presum-
ably due to differential effects of HIF and VEGFR signaling.
Differential expression of isoforms of the transcription factor
HIF and the subsequent induction of target genes such as
VEGFR-1 and VEGFR-2 appear responsible for the response to
hypoxia in hypertrophied hearts. Within the HIF family, three
protein subtypes have been described, of which HIF-1a and HIF-
2a have been characterized in the greatest detail [19]. HIF is a
heterodimer composed of an alpha-(HIF-a) and beta-subunit
(HIF-b). While HIF-b is expressed constitutively, expression of
HIF-a is directly regulated by low tissue pO2. Under normoxic
conditions, HIF-a is the target of hydroxylation by prolyl
hydroxylases. The hydroxylated protein is then ubiquitinated
and degradation by the proteosome. Under hypoxia, HIF-a
stabilizes and translocates to the nucleus as a heterodimer with the
b-subunit and activates gene transcription. In the present
experiments, hypertrophy increased HIF-1a expression and
activity without evidence of tissue hypoxia. This result is consistent
with evidence that HIF-1a expression and activation can be
promoted by non-hypoxic mechanisms likely to be active in
hypertrophying hearts, including increased reactive oxygen species
production, mechanical stretch-activated channels, and phospha-
tidylinositol 3-kinase (PI3-K)-dependent Akt phosphorylation [20].
The relative roles of the different HIF moieties remain unclear.
Independent, complementary, redundant, and opposing functions
have all been described for HIF-1a and HIF-2a, depending upon
developmental stage, experimental conditions, activating stimulus,
and cell type [21–25]. Similarly, it appears that expression of
VEGFR-1 and VEGFR-2 can be primarily regulated by HIF-1a,
HIF-2a, or at times both [26–30]. Within the VEGF receptor
family, VEGFR-2 is better characterized and plays an important
role in induction of angiogenesis. Reduced expression of VEGFR-
2 in hypertrophied myocardium is one possible explanation of
decreased capillary density in these hearts. As the systemic
response to hypoxia in animals that underwent aortic banding
appears to be intact, it seems likely that alteration in myocardial
gene expression and protein content in response to pressure
overload results in inhibition of HIF-2 and VEGFR-2 expression
and, thus, capillary growth.
Increased expression of VEGFR-1 by HIF-1a has been well
established, but the consequence of activation of this signalling
pathway and its role in stimulating VEGFR-2 expression is not as
well characterized [31,32]. VEGFR-1 is expressed in two forms
(both of which are detectable by the antibody used in our
experiments). These include the full-length membrane bound
receptor, capable of transducing a cellular signal, and a soluble
receptor, capable of sequestering ligand or dimerizing with the
full-length receptor to prevent signal transduction [33,34]. It is
known that the extracellular portion and the soluble fraction of
VEGFR-1 have a 10-fold higher affinity for the VEGF ligand with
limited or no detectable autophosphorylation activity. Further-
more, VEGFR-2 is phosphorylated approximately 10-fold more
efficiently upon ligand binding [32]. Seetharam et al. demonstrated
a high binding affinity of VEGFR-1 to VEGF without generating
a mitogenic response in transfected NIH3T3 fibroblasts that over-
expressed VEGFR-1 [35]. As a consequence, VEGFR-1 has been
referred to by some as an impaired protein kinase that can
function as a ‘‘decoy’’ receptor [36,37], particularly in its soluble
form. Based on this information, excessive expression of VEGFR-1
could result in increased binding to VEGF ligand, resulting in
competitive suppression of VEFGR-2 activation and the angio-
genic response. Hiratsuka et al. reported that VEGFR-1 is essential
for normal development of the vasculature [38]. They showed that
mice expressing a truncated form of VEGFR-1 die at embryonic
day 8.5, whereas mice lacking only the VEGFR-1 tyrosine kinase
domain survived and showed normal development of the
vasculature [38]. Therefore, based on the increased binding
affinity and decreased signaling capability, VEGFR-1 does appear
to have the ability to act as a ‘‘decoy’’ receptor as well as an
angiogenesis-inducing receptor [39]. As a result, the marked
increase in HIF-1a and VEGFR-1 expression in the hypertrophied
myocardium, in combination with the attenuated HIF-2a and
VEGFR-2 response, most likely contribute to the observed lack of
angiogenic response to hypoxia in our studies. Interestingly,
Ahmad et al. showed that elevated expression of soluble VEGFR-1
in the inhibits placental angiogenesis [40], a result that is consistent
with our observations.
Limitations of the study
Even though we believe that our experimental design was
appropriate to test the primary hypothesis (i.e. that the pro-
angiogenic response to hypoxia would be blunted in hypertrophied
hearts), the conclusion that differential VEFGR-subtype expres-
sion and activity might be the cause for this effect are based upon
association and the current state of knowledge. To substantiate the
cause-effect relationship, future experiments using VEGFR-1
knock-out mice or siRNA approaches to selectively suppress
VEGFR-1 expression in wild type animals are necessary. The
cellular source(s) of the various HIF and VEGF subtypes were also
not determined by the present experiments; detailed immunohis-
tochemical studies and in vitro experiments will be necessary to
distinguish the relative contributions from cardiomyocytes,
endothelial cells, fibroblasts, and smooth muscle. Other mecha-
nisms of angiogenesis inhibition, occurring at different stages of
hypertrophy, may also be involved. For example, accumulation of
p53 has recently been shown inhibit HIF-1a activity and thereby
hinder angiogenesis during the later stages of severe pressure
overload hypertrophy progressing to contractile failure [41].
Conclusion
Our studies provide evidence that pressure overload hypertrophy
is associated with decreased capillary density, increased expression
of HIF-1a, and the potential decoy VEGF receptor, VEGFR-1, and
decreased expression of HIF-2a and VEGFR-2. Unlike the non-
hypertrophied heart, hypoxia further increased VEGF-1 expression
without a concomitant increase in the pro-angiogenic receptor,
VEGFR-2. These changes occurred relatively early during the
development and progression of hypertrophy. It appears that HIF-
2a signaling is necessary to mount a myocardial angiogenic
response. This differential regulation of HIF-1a and HIF-2a in
pressure overload hypertrophy may explain the lack of angiogenesis
as muscle mass increases and help determine the eventual
development of contractile dysfunction and ventricular dilation.
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